A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer

BackgroundAnlotinib is a novel oral small-molecule tyrosine kinase inhibitor (TKI), which can inhibit angiogenesis. The purpose of this study was to evaluate the efficacy and safety of anlotinib combined with chemotherapy in patients with metastatic triple-negative breast cancer (TNBC).MethodsThis p...

Full description

Bibliographic Details
Main Authors: Jia-Yi Huang, Xiao-Feng Xie, Xue-Lian Chen, Qiu-Yi Zhang, Li-Ping Chen, Xue Bai, Xiao-Feng Lan, Lin Song, Jin-Feng Guo, Cai-Wen Du
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
anlotinib
angiogenesis
chemotherapy
triple-negative breast cancer (TNBC)
tyrosine kinase inhibitor (TKI)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1122294/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1122294/full

Similar Items